STOKE THERAPEUTICS, INC.
STOK US86150R1077
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -59% | -60% | -42% | 88% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Kaye Edward M. Md O |
25.09 USD |
42,461 Sold |
1,065,206 USD |
03/10/2025 | 03/10/2025 |
| Allan Jonathan SR OFF |
25.07 USD |
10,000 Sold |
250,650 USD |
03/10/2025 | 03/10/2025 |
| Ticho Barry SR OFF |
23.64 USD |
5,343 Sold |
126,316 USD |
01/10/2025 | 01/10/2025 |
| Allan Jonathan SR OFF |
20.07 USD |
6,345 Sold |
127,317 USD |
29/08/2025 | 03/09/2025 |
| Kaye Edward M. Md O |
20.13 USD |
45,996 Sold |
925,858 USD |
29/08/2025 | 03/09/2025 |
| Kaye Edward M. Md O |
20.14 USD |
14,860 Sold |
299,260 USD |
29/08/2025 | 02/09/2025 |
| Ticho Barry CMO |
19.87 USD |
5,501 Sold |
109,325 USD |
02/09/2025 | 02/09/2025 |
| Allan Jonathan SR OFF |
20.14 USD |
14,922 Sold |
300,492 USD |
29/08/2025 | 02/09/2025 |
| Kaye Edward M. Md O |
20.00 USD |
1,029 Sold |
20,580 USD |
29/08/2025 | 29/08/2025 |
| Allan Jonathan SR OFF |
20.00 USD |
850 Sold |
17,000 USD |
29/08/2025 | 29/08/2025 |